Psychotic Disorders Clinical Trial
Official title:
The Hong Kong Morbidity Survey 2010 Part 3: Epidemiology Study of Psychosis Disorder and Sub-clinical Psychotic Experiences
Purpose Psychotic disorders (including schizophrenia) are complex neurobehaviour disorders
influenced by genetic, neurodevelopmental, neurochemical, as well as psychosocial factors.
Despite significant progresses in pharmacotherapy, the disorder often results in long-term
disability (ranked globally amongst the top ten leading causes of disability-adjusted life
years, DALYS), often associated with extensive cost, burden, morbidity and mortality.
Objective / hypothesis The study aims to (1) measure the prevalence of psychotic symptoms in
the Hong Kong population; (2) explore associated risk and protective factors for the
expression of psychotic symptoms; (3) characterize the functional disability in people with
psychotic symptoms; and (4) study the determinant of clinical presentation or
non-presentation in people with psychotic symptoms.
Design, subjects and study instrument The survey will be conducted with a two-phase design.
The first phase interviews will include approximately 5,000 subjects with structured
assessments serving diagnostic criteria for CMD, screening instruments for psychotic
disorder, substance misuse and suicidal behaviours, functioning, service use and
demographics. The second phase comprises of clinician interviews for psychotic disorder and
"at risk mental state" and other variables including neurocognitive, help seeking, stigma
and well-being.
Analysis Prevalence estimates will be weighted, expressed as rates and confidence intervals.
Comorbidity will be estimated using Latent Class Analysis (LCA) Logistic regression will be
used to identify significant factors associated with mental disorders.
Psychotic disorders (including schizophrenia) are complex neurobehaviour disorders
influenced by genetic, neurodevelopmental, neurochemical, as well as psychosocial factors.
Amongst these risk factors, recent findings have highlighted the roles of immigration, urban
upbringing, high paternal age, psychoactive substance abuse, as well as stressful early
experiences. Despite significant progresses in pharmacotherapy, the disorder often result in
long-term disability ranked globally amongst the top ten leading causes of
disability-adjusted life years (DALYS, WHO). The World health Organization concludes that
the burden and human suffering associated with psychosis is extensive and results in high
service and societal costs. Identification and treatment of psychotic disorders (sometimes
referred to as Severe Mental Illness, or SMI) is a priority in most mental health services
worldwide. However such efforts are challenging because of the help-seeking is severely
compromised by reluctance, stigmatization, lack of knowledge, and poor accessibility. This
has resulted in long delays before treatment, as well as lack of information about the
community prevalence, and associated disability and risk factors for psychosis (ref DUP
paper). Availability of these data for Hong Kong will facilitate service planning, early
detection and intervention efforts, as well as the consideration of population level
preventative strategies.
Availability data suggest that the prevalence of psychosis in the community is substantially
higher (5.5-28%, vanos 09) than the prevalence of treated disorder (1-3.5%, vanos09 ),
raising important questions about the what determines whether and when psychotic disorders
are intercepted in a particular service setting. It is vital to also to obtain information
about the untreated cases, in terms of risk factors and protective factors, disability, as
well as obstacles to help-seeking.
Community level data for psychotic disorders in Hong Kong is sparse and there has been no
territory-wide population-level epidemiology. The Hong Kong population has several
distinctive features which are of particular scientific interest and public health concern
in relation to psychosis. Although the overall prevalence of substance abuse is low, there
is disproportionate use of ketamine in Hong Kong, which interferes with glutaminergic
neurotransmission. The relationship between ketamine use and risk for psychosis is of
aetiological and clinical interest. In addition, the unique societal context of Hong Kong
has resulted in a high proportion of immigrants from China. Moreover, a cohort of people
with relatively high paternal age is entering the risk period of developing psychotic
disorders (resulting from older man from Hong Kong and younger women from neighbouring parts
of China in the previous decades).
Previous relevant study included a district survey, which was more than a quarter of a
century old, and was of limited generalization value because of the uneven socioeconomic
distribution amongst Hong Kong's 18 districts, resulting in likely uneven distribution of
individual with psychosis amongst them. Other relevant data included data of treated new
onset cases from Hong Kong's early intervention service (EASY, annual incidence of at least
600 cases under 25, and estimated 1200-1500 in all age groups), with the limitations of
treated incidence discussed above.
The investigators propose a territory-wide epidemiological study of psychosis. The study
aims to (1) measure the prevalence of psychotic symptoms in the Hong Kong population; (2)
explore associated risk and protective factors for the expression of psychotic symptoms; (3)
characterize the functional disability in people with psychotic symptoms; and (4) study the
determinant of clinical presentation or non-presentation in people with psychotic symptoms.
;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00226278 -
Safety Study of ORG 34517 for Major Depression With Psychotic Features
|
Phase 2 |